Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02286843
Title Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

Her2-receptor negative breast cancer

Therapies

Trastuzumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field